Sei Investments Co. Has $4.86 Million Holdings in Arcutis Biotherapeutics, Inc. $ARQT

Sei Investments Co. lifted its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) by 97.7% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 206,141 shares of the company’s stock after purchasing an additional 101,855 shares during the quarter. Sei Investments Co.’s holdings in Arcutis Biotherapeutics were worth $4,857,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. State of Wyoming increased its stake in shares of Arcutis Biotherapeutics by 62.9% in the 1st quarter. State of Wyoming now owns 18,434 shares of the company’s stock valued at $434,000 after acquiring an additional 7,117 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Arcutis Biotherapeutics by 29.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 17,597 shares of the company’s stock valued at $415,000 after acquiring an additional 4,000 shares in the last quarter. KBC Group NV lifted its holdings in shares of Arcutis Biotherapeutics by 43.2% in the first quarter. KBC Group NV now owns 4,376 shares of the company’s stock valued at $103,000 after purchasing an additional 1,321 shares in the last quarter. Swiss National Bank lifted its stake in Arcutis Biotherapeutics by 2.5% during the 1st quarter. Swiss National Bank now owns 218,200 shares of the company’s stock valued at $5,141,000 after acquiring an additional 5,400 shares in the last quarter. Finally, Independent Financial Group LLC purchased a new position in Arcutis Biotherapeutics during the first quarter worth about $210,000.

Insider Buying and Selling

In other Arcutis Biotherapeutics news, Director Sue-Jean Lin sold 4,946 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $24.38, for a total value of $120,583.48. Following the sale, the director owned 27,567 shares of the company’s stock, valued at $672,083.46. This trade represents a 15.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Todd Watanabe sold 4,375 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.12, for a total value of $114,275.00. Following the completion of the sale, the insider directly owned 717,203 shares in the company, valued at $18,733,342.36. The trade was a 0.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 16,894 shares of company stock valued at $422,044. 9.40% of the stock is owned by insiders.

Arcutis Biotherapeutics Trading Up 4.1%

NASDAQ ARQT opened at $27.10 on Thursday. The stock’s 50-day simple moving average is $25.87 and its two-hundred day simple moving average is $24.68. The company has a market capitalization of $3.39 billion, a price-to-earnings ratio of -903.03 and a beta of 1.49. Arcutis Biotherapeutics, Inc. has a twelve month low of $13.69 and a twelve month high of $31.77. The company has a quick ratio of 2.46, a current ratio of 2.68 and a debt-to-equity ratio of 0.54.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.05. Arcutis Biotherapeutics had a negative return on equity of 1.41% and a negative net margin of 0.57%.The business had revenue of $129.86 million during the quarter, compared to analyst estimates of $118.85 million. Research analysts forecast that Arcutis Biotherapeutics, Inc. will post 0.16 EPS for the current fiscal year.

Key Headlines Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong revenue growth and earnings beat: Second-quarter net product revenue reached $129.9 million, up 59% from the prior-year quarter and 23% sequentially. Adjusted earnings of $0.11 per share exceeded analyst estimates ranging from $0.06 to $0.09, compared with a $0.13 loss a year earlier. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Raised 2026 sales outlook: Arcutis increased its full-year net product sales guidance to $525 million–$540 million, signaling confidence in sustained demand for ZORYVE. The company also maintained positive operating cash flow during the quarter. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Expanded growth opportunities: The FDA approved ZORYVE cream 0.3% for plaque psoriasis in children as young as two. The FDA also accepted an application for use in infants aged three to 24 months with mild-to-moderate atopic dermatitis, with a target decision date of February 23, 2027. Enrollment is complete in a Phase 2 vitiligo study, with results expected in the fourth quarter of 2026. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Insider sales appear administrative: Three executives sold a combined 6,560 shares at approximately $26.12 per share. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, limiting their significance as a bearish signal. SEC Insider Trading Filing

Wall Street Analyst Weigh In

ARQT has been the topic of several research analyst reports. Wall Street Zen raised Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday, May 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a report on Wednesday, June 24th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.